phrykt

Cardiff Oncology, Inc. (CRDF): who owns it and who trades it

As of Nov 16, 2026, CRDF insiders reported 4 purchases worth $1.1M in the last 12 months. The largest buyer was Gary W Pace (Director), with $1M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cardiff Oncology

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CRDF

104 funds and institutions reported CRDF shares worth $24.3M at the end of Q2 2026, about 27% of the company. The largest holder is Laurion Capital Management LP with 4.5%.

Funds and institutions (13F) 27%Everyone else 73%

10 largest owners, by share of the company

Laurion Capital Management LP4.5%
Vanguard Capital Management LLC4.2%
Pfizer Inc3.5%
Franklin Resources Inc1.8%
BlackRock, Inc.1.4%
Blair William & Co1.3%
Geode Capital Management, LLC1.2%
UBS Group AG0.9%
Jane Street Group, LLC0.9%
Vanguard Fiduciary Trust Co0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Laurion Capital Management LP3.10M4.53%$4M+17%
Vanguard Capital Management LLC2.90M4.24%$3.8M+1%
Pfizer Inc2.41M3.53%$3MNo change
Franklin Resources Inc1.21M1.76%$1.6MNo change
BlackRock, Inc.972,8731.42%$1.3M-76%
Blair William & Co912,5131.33%$1.2M-1%
Geode Capital Management, LLC820,0621.20%$1.1M-49%
UBS Group AG638,6990.93%$830K+59%
Jane Street Group, LLC607,9000.89%$790K+1416%
Vanguard Fiduciary Trust Co410,6020.60%$534K-8%
AQR Capital Management LLC346,3530.51%$450K+424%
State Street Corp331,3950.48%$431K-72%
Hrt Financial LP272,7860.40%$354K–
Flputnam Investment Management Co247,4740.36%$322K-58%
Morgan Stanley246,0950.36%$320K+337%
BNP Paribas Financial Markets228,4610.33%$297K+1647%
X-Square Capital, LLC205,7000.30%$267K–
Gsa Capital Partners LLP173,2740.25%$225K+41%
Marshall Wace, LLP162,2140.24%$211K–
Bank of New York Mellon Corp161,6890.24%$210K-47%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CRDF insiders reported $1.1M of open-market purchases and $0 of sales.

Purchases, 12 months
$1.1M
4 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jul 14, 2026
Filed Jul 16, 2026

Purchases and sales by month

$1.1M$1.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 14, 2026Gary W PaceDirectorPurchase687,285$1.46$1MForm 4
Jul 14, 2026Mani MohindruCEOPurchase34,364$1.46$50.2KForm 4
Jun 18, 2026Mani MohindruCEOPurchase24,703$1.21$29.9KForm 4
Jun 18, 2026Gary W PaceDirectorPurchase30,000$1.22$36.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Gary W PaceDirector$1M–Jul 14, 2026
Mani MohindruChief Executive Officer, Director$80.1K–Jul 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CRDF short interest

High short interest. 15.8% of CRDF shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 32%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.26M CRDF shares were sold short, 15.8% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 397,871 shares, buying them all back would take about 30.8 trading days (days to cover).

Shares short, % of all shares

15.8%May 15Oct 3028.2%

Days to cover

30.8May 15Oct 3034.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.26M15.76%+1%397,87130.8
Oct 15, 202612.12M15.58%+0%433,44128.0
Sep 30, 202612.07M15.52%-2%702,31517.2
Sep 15, 202612.31M15.82%+5%1.02M12.1
Aug 31, 202611.68M15.02%-2%643,45418.2
Aug 14, 202611.90M15.29%-2%778,97215.3
Jul 31, 202612.19M17.84%+1%1.32M9.3
Jul 15, 202612.09M17.68%-6%1.96M6.2
Jun 30, 202612.81M18.74%-21%1.65M7.8
Jun 15, 202616.15M23.62%-11%2.03M8.0
May 29, 202618.13M26.52%+1%1.48M12.3
May 15, 202618.02M26.35%-2%670,31426.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cardiff Oncology company events

Cardiff Oncology filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 27, 2026.

  1. Oct 27, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  2. Oct 22, 2026VoteReported shareholder vote results. Filing
  3. Sep 14, 2026AgreementCardiff Oncology, Inc. and Nerviano Medical Sciences, S.r.l. Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Jul 16, 2026AgreementCardiff Oncology, Inc. entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to sell to such investors 8,571,429 shares of common stock of the Company and accompanying warrants to purchase up to 8,571,429 shares of Common Stock, at a… Filing
  6. Jun 11, 2026VoteReported shareholder vote results. Filing
  7. Jun 3, 2026AnnouncementShared information with investors. Filing
  8. May 29, 2026AgreementAs previously disclosed, on May 19, 2026, Cardiff Oncology, Inc. filed a lawsuit against Nerviano Medical Sciences S.r.l. Filing
  9. May 19, 2026AnnouncementCardiff Oncology, Inc. filed a lawsuit against Nerviano Medical Sciences S.r.L disputing NMS’s allegation that the Company materially breached its license agreement (Agreement) for onvansertib. Filing
  10. May 14, 2026ResultsReleased financial results. Filing
  11. Apr 9, 2026LeadershipCardiff Oncology, Inc. announced that Josh Muntner has been appointed the Company’s Chief Financial Officer effective April 6, 2026. Filing
  12. Apr 2, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  13. Feb 25, 2026AnnouncementShared information with investors. Filing
  14. Feb 24, 2026DealCompleted a purchase or sale of a business or assets. Filing
  15. Jan 27, 2026LeadershipDr. Mark Erlander, Ph.D., CEO of Cardiff Oncology, Inc., and James Levine, CFO of the Company stepped down from their respective roles at the Company as part of a strategic leadership review. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cardiff Oncology financials

Famous investors that hold CRDF

2 of the 50 well-known investors we track reported holding CRDF in their latest 13F filing. The largest position is Israel Englander's, worth $141K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026116,375$141K0.0%-13%
Jim Simons · Renaissance TechnologiesQ3 202651,800$62.7K0.0%+272%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CRDF in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Highbridge Capital Management, LLC13G5.8%
Nov 16, 2026Highbridge Capital Management, LLC13G5.8%

Questions about Cardiff Oncology, Inc. (CRDF) stock

Who owns the most CRDF stock?

The largest reported owner of Cardiff Oncology, Inc. (CRDF) is Laurion Capital Management LP, with 4.5% of the company. In total, 104 funds and institutions reported holding CRDF at the end of Q2 2026, together about 27% of the shares. See the largest owners.

Are CRDF insiders buying or selling?

In the last 12 months, CRDF insiders reported 4 open-market purchases worth $1.1M and no sales. The latest trade was on Jul 14, 2026. See every trade.

What is the short interest in CRDF?

As of Oct 30, 2026, 12.26M CRDF shares were sold short, 15.8% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 397,871 shares, buying them all back would take about 30.8 trading days (days to cover). See the history.

Which famous investors hold CRDF?

2 of the 50 well-known investors we track reported CRDF in their latest 13F filing, including Israel Englander, Jim Simons. The largest position is worth $141K. See all holders.

Executive pay

Cardiff Oncology's chief executive was paid a total of $3M for the year ended Dec 31, 2025, up 26% from $2.4M the year before. In the last 12 months, Cardiff Oncology's executives and directors bought $1.1M of stock on the open market and sold none.

Chief executive, total pay$3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$891KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.